Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells

British Journal of Cancer

Volumn 84, Issue 5, 2001, Pages 686-690

  Larsen, S S ^a   Heiberg, I ^a   Lykkesfeldt, A E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Anti oestrogen resistance; Bcl 2; EB1089; ER ; MCF 7; Vitamin D analogue

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PROTEIN BCL 2; SEOCALCITOL; TAMOXIFEN; TUMOR MARKER; VITAMIN D DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCITRIOL; CELL DIVISION; DOWN-REGULATION; DRUG RESISTANCE; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0035793835     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1646     Document Type: Article

References (44)

1. MCF7/LCC9: An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182.780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen
2. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3
3. Mechanisms of transcriptional activation of bcl-2 gene expression by 17 beta-oestradiol in breast cancer cells
4. Reversal of hypercalcemia with the vitamin D analogue EB1089 in a human model of squamous cancer
5. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study
6. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy
7. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer
8. Seocalcitol (EB 1089): A vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation
9. Apoptosis and Bcl-2 expression in relation to age, tumor characteristics and prognosis in breast cancer
10. Tamoxifen as an agonist for metastatic breast cancer
11. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer
12. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
13. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780
14. EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells in vivo and in vitro
15. R-6
16. The expression of Ki-Sl and BCL-2 and the response to primary tamoxifen therapy in elderly patients with breast cancer
17. Clinical significance of bcl-2 gene expression in human breast cancer tissues
18. Resistance of human breast-cancer cells to the pure steroidal anti-oestrogen ICI 182, 780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness
19. Acquired antiestrogen resistance in MCF-7 human breast cancer sublines is not accomplished by altered expression of receptors in the ErbB-family
20. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis
21. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells
22. Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines
23. Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen resistant variant subline, AL-1
24. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164, 384 and ICI 182, 780 sensitive human breast cancer cell line
25. Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment
26. Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells
27. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells
28. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53
29. Differential effects of 1, 25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant
30. Dissociation of vitamin D-3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells
31. Overexpression of BCL-x protein in primary breast cancer is associated with high tumor grade and nodal metastases
32. Checkpoints of dueling dimers foil death wishes
33. The value of estrogen and progesterone receptors in the treatment of breast cancer
34. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer
35. 17beta-Estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence
36. Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation
37. P53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients
38. Comparative effects of 1, 25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells
39. 1alpha, 25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells
40. Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens
41. Vitamin D compounds as potential therapeutics for estrogen-independent breast cancer
42. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells
43. Vitamin D derivatives inhibit the mitogenic effects of IGF-I on MCF-7 human breast cancer cells
44. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells